心舒宁合剂对舒张性心力衰竭患者BNP、CA125和CRP的影响分析

Effect of Xinshuning mixture on serum levels of BNP, CA125 and CRP in patients with diastolic heart failure

摘要:

目的探讨心舒宁合剂辅助治疗舒张性心力衰竭（DHF）患者的临床效果及对患者外周血脑钠肽（BNP）、糖类抗原125（CA125）和C 反应蛋白（CRP）的影响。方法选取2015 年1~12 月该院心血管内科收治的DHF 患者120 例，根据就诊顺序随机分为心舒宁组和常规组各60 例。两组均采用西医基础治疗，心舒宁组同时给予心舒宁合剂辅助治疗，疗程2 个月，对比临床效果。结果治疗后，心舒宁组与常规组比较，6 min步行距离、心脏彩超E 峰/A 峰和左室射血分数均高于常规组，差异有统计学意义（t =3.767、3.866 和5.474， p=0.000、0.000 和0.000）；心舒宁组的等容舒张时间低于常规组，差异有统计学意义（ t=8.36，p =0.000）；心舒宁组外周血BNP、CA125 和CRP 水平低于常规组，差异有统计学意义（t =3.456、6.317 和6.939，p =0.003、0.000 和0.000）；治疗2 个月后，心舒宁组的总有效率95.00%（57/60）高于常规组81.67%（49/60），差异有统计学意义（χ2=5.175，p =0.023）。结论心舒宁合剂辅助治疗DHF患者能够提高患者的心功能水平，降低外周血BNP、CA125 和CRP水平，提高临床治疗效果。

Abstract:

Objective To investigate the clinical effect of Xinshuning mixture in the treatment of patients with diastolic heart failure (DHF) and its effect on brain natriuretic peptide (BNP), carbohydrate antigen 125 (CA125) and C-reactive protein (CRP). Methods From January 2015 to December 2015 in the Department of Cardiology of our hospital, 120 cases of DHF patients were randomly divided into Xinshuning group and control group with 60 cases in each group. The control group accepted Western medicine treatment, and the Xinshuning group accepted both Xinshuning mixture and Western medicine. The treatment lasted for 2 months. The effect was compared between the 2 groups after treatment. Results After treatment, 6-min-walking distance, heart color Doppler peak E/A and left ventricular ejection fraction increased in the Xinshuning group compared to those in the control group (p < 0.05), while isovolumic relaxation time was significantly shortened in the Xinshuning group (p < 0.05). After treatment, the peripheral blood levels of BNP, CA125 and CRP in the Xinshuning group were significantly lower than those in the control group (p < 0.05). After 2 months of treatment, the total efficiency was 95.00% (57/60) in the Xinshuning group which was higher than 81.67% (49/60) in the control group (p < 0.05). Conclusions Xinshuning mixture can significantly improve cardiac function of DHF patients, reduce the serum levels of BNP, CA125 and CRP, and improve the clinical treatment effect.